Navigation Links
Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
Date:8/26/2008

SEATTLE, Aug. 26 /PRNewswire/ -- Omeros Corporation today announced the publication of the results from a Phase 1/Phase 2 trial investigating OMS103HP in arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. OMS103HP is an investigational drug product that is added to arthroscopic irrigation solution and is designed to improve postoperative knee function and motion, reduce postoperative pain and allow patients an earlier return to work. The article titled "Novel Drug Product to Improve Joint Motion and Function and Reduce Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction" appeared in the June 2008 edition of Arthroscopy: The Journal of Arthroscopic and Related Surgery.

The article reports on a prospective, double-blind, vehicle-controlled study of 30 evaluable patients undergoing arthroscopic allograft ACL reconstruction. Patients were randomized across two arms to receive either standard arthroscopic irrigation solution or the same solution with OMS103HP added to it. Patients were monitored for safety, and efficacy endpoints assessed over the 30-day postoperative period included measurements of knee function and motion, leg muscle strength, pain and return to work.

Results of the study demonstrated a statistically significant improvement in knee function, range of motion, quadriceps and hamstring muscle strength, pain management and return to work in OMS103HP-treated patients. The incidence of adverse events and abnormal clinical laboratory values for OMS103HP and the control arm were similar.

"We are pleased that Arthroscopy, a well-respected and peer-reviewed journal, chose to publish these clinical results obtained using OMS103HP, the most clinically advanced of our PharmacoSurgery product candidates," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "We look forward to completing our ongoing Phase 3 clinical program further evaluating the safety and efficacy of OMS103HP."

OMS103HP is
'/>"/>

SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... The issue: Mylan Pharmaceuticals ULC Canada, in consultation with Health ... 0.4 mg/metered dose due to the product missing the "dip ... A missing "dip tube" could pose a potential problem ... may lead patients to believe they are receiving the nitroglycerin, ... receiving nitroglycerin could place them at risk for either a ...
(Date:9/19/2014)... , Sept. 19, 2014 Medical science ... relationships with key opinion leaders (KOLs) who can ... Despite the critical nature of the MSL function, ... including altering the landscape for creating and maintaining ... to research, the oversight responsibility for the MSL ...
(Date:9/19/2014)... , Sept. 19, 2014 Harwood Feffer LLP ... board of directors of PDL BioPharma, Inc. ("PDL" or ... the board has breached its fiduciary duties to shareholders ... September 16, 2014, the Company disclosed: "On September 11, ... accounting firm, Ernst & Young LLP ("EY"), that it ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... 2011 ,   EP ... of the Year Award at the European Mediscience,Awards, sponsored ... award, which honours clear and concise commentary in the,pharma ... research houses or specialist websites dedicated to,providing sharp, perceptive ...
... 24, 2011 New Phase 2 clinical trial data ... of Medicine show that patients with moderate to ... bardoxolone methyl for 52 weeks experienced a sustained improvement ... by estimated glomerular filtration rate (eGFR). The data were ...
Cached Medicine Technology:EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 2EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 2New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 4
(Date:9/21/2014)... Colorado (PRWEB) September 21, 2014 High ... ten teams of disabled and able-bodied athletes rafted the ... completed a ropes course in pursuit of outdoor adventure. ... from national non-profit World T.E.A.M. Sports, disabilities proved to ... who successfully completed the three stage event. , Each ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... http://www.thegranuflolawsuit.com/ ) have been added over the past ... claims that allege serious cardiovascular injuries caused by ... A Case List updated on September 15th shows ... in the U.S. District Court, District of Massachusetts. ...
(Date:9/21/2014)... An experienced review website in the global market, ... and announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ), GoDaddy and ... There has been a boom in websites in recent ... increase in the number of web hosting companies that ... prices. VPS (Virtual Private Server) is the method of ...
(Date:9/21/2014)... 21, 2014 “Cluster headaches are sometimes ... and difficult to resolve,” said Steve Young of Ew ... of a pain that is more intense.” , “It ... cluster headaches, or migraines, that medical research is pointing ... system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Recently, BambooIndustry.com, ... a special offer for its bamboo panels ( http://www.bambooindustry.com/products/bamboo-panel/ ... the market; all of them are available at discounted ... , The company’s discounted bamboo panels are ... made of quality materials. Each of them is finely ...
Breaking Medicine News(10 mins):Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2
... with the non-profit organization HopeLab to deliver innovative interventions ... young people with chronic illnesses . Their first joint ... and young adults with cancer by offering free of ... works. It gives young people with cancer a sense ...
... are more active and have less body fat than ... today at the 54th American College of Sports Medicine ... associated with higher levels of self-reported leisure-time physical activity ... weight, status, and neighborhood, environment, walkability, and income between ...
... lawmakers to set aside 30 billion dollars over five years ... proposal fell short of funds needed to battle the global ... would visit Africa in June to assess HIV/AIDS-fighting strategies in ... works and what does not in battling the deadly disease. ...
... holy city of Najaf on Friday after receiving treatment for ... of the most powerful parties in the parliament, spent nearly ... in the United States and treatment in Iran. ... there for a long time, after he finished his initial ...
... study has found that people can be encouraged to walk ... if they are given the right kind of help. ... the Scottish Physical Activity Research Collaboration (SPARColl), the study suggests ... of waysface to face advice or telephone support, using pedometers, ...
... found three new drugs that may help transform the ... thus giving hope for chronically infected patients. ,The ... Hiroyu Hatano, and Steven Deeks at San Francisco General ... new drugs are the HIV integrase inhibitors, R5 inhibitors, ...
Cached Medicine News:Health News:CIGNA HealthCare Teams With HopeLab to Help Blast Teen Cancer 2Health News:Dog Owners More Active, Leaner 2Health News:Bush Seeks Doubling of AIDS-fighting Funds 2Health News:Top Iraqi Shiite Leader Returns Home 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0454....
Medicine Products: